JP6738285B2 - ヒト及びカニクイザルｃｄ３イプシロンに結合する抗体 - Google Patents

ヒト及びカニクイザルｃｄ３イプシロンに結合する抗体 Download PDF

Info

Publication number
JP6738285B2
JP6738285B2 JP2016569639A JP2016569639A JP6738285B2 JP 6738285 B2 JP6738285 B2 JP 6738285B2 JP 2016569639 A JP2016569639 A JP 2016569639A JP 2016569639 A JP2016569639 A JP 2016569639A JP 6738285 B2 JP6738285 B2 JP 6738285B2
Authority
JP
Japan
Prior art keywords
antibody
human
cells
seq
cynomolgus monkey
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016569639A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017516786A (ja
JP2017516786A5 (enExample
Inventor
ゲオルク ティーフェンタラー，
ゲオルク ティーフェンタラー，
エッケハルト メスナー，
エッケハルト メスナー，
ヴァレリア リフケ，
ヴァレリア リフケ，
ヨーゼフ プラッツァー，
ヨーゼフ プラッツァー，
ソニヤ オフナー，
ソニヤ オフナー，
クリスティアーネ イェーガー，
クリスティアーネ イェーガー，
ミルコ リッター，
ミルコ リッター，
Original Assignee
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト filed Critical エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト
Publication of JP2017516786A publication Critical patent/JP2017516786A/ja
Publication of JP2017516786A5 publication Critical patent/JP2017516786A5/ja
Application granted granted Critical
Publication of JP6738285B2 publication Critical patent/JP6738285B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2016569639A 2014-05-28 2015-05-22 ヒト及びカニクイザルｃｄ３イプシロンに結合する抗体 Expired - Fee Related JP6738285B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14170140.9 2014-05-28
EP14170140 2014-05-28
EP14180572.1 2014-08-11
EP14180572 2014-08-11
PCT/EP2015/061457 WO2015181098A1 (en) 2014-05-28 2015-05-22 Antibodies binding to human and cynomolgus cd3 epsilon

Publications (3)

Publication Number Publication Date
JP2017516786A JP2017516786A (ja) 2017-06-22
JP2017516786A5 JP2017516786A5 (enExample) 2020-07-09
JP6738285B2 true JP6738285B2 (ja) 2020-08-12

Family

ID=53268799

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016569639A Expired - Fee Related JP6738285B2 (ja) 2014-05-28 2015-05-22 ヒト及びカニクイザルｃｄ３イプシロンに結合する抗体

Country Status (13)

Country Link
US (3) US20170233475A1 (enExample)
EP (2) EP3763739A1 (enExample)
JP (1) JP6738285B2 (enExample)
KR (1) KR20170003591A (enExample)
CN (1) CN106459201A (enExample)
AU (1) AU2015266077A1 (enExample)
BR (1) BR112016022819A2 (enExample)
CA (1) CA2942453A1 (enExample)
IL (1) IL247740A0 (enExample)
MX (1) MX2016015389A (enExample)
RU (1) RU2016151235A (enExample)
SG (1) SG11201609950YA (enExample)
WO (1) WO2015181098A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL313608A (en) 2015-12-09 2024-08-01 Hoffmann La Roche Antibody against CD20 type II to reduce the formation of antibodies against drugs
WO2017150762A1 (ko) * 2016-02-29 2017-09-08 (주)메디톡스 항-CD3γε 항체 및 이의 용도
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
CN118126180A (zh) * 2016-12-22 2024-06-04 第一三共株式会社 抗cd3抗体和包含所述抗体的分子
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
JP2020521791A (ja) 2017-06-02 2020-07-27 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のためのｉｉ型抗ｃｄ２０抗体及び抗ｃｄ２０／ｃｄ３０二重特異性抗体
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
US11319371B2 (en) 2017-06-05 2022-05-03 Numab Therapeutics AG Anti-CD3 antibodies
JP7009517B2 (ja) 2017-06-21 2022-01-25 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ ｇｐ１２０およびｃｄ３を標的とする多重特異性抗体
US12486325B2 (en) 2017-09-21 2025-12-02 WuXi Biologics Ireland Limited Anti-CD3epsilon antibodies
CN111108119B (zh) * 2017-09-21 2022-11-15 上海药明生物技术有限公司 新型抗CD3ε抗体
EP3717632B1 (en) 2017-11-30 2022-10-26 F. Hoffmann-La Roche AG B-cell cultivation method
CN120399075A (zh) * 2018-03-14 2025-08-01 诺维莫尼公司 抗-CD3ε抗体及其应用方法
BR112020023508A2 (pt) * 2018-05-24 2021-03-30 Janssen Biotech, Inc. Anticorpos anti-cd3 e usos dos mesmos
TW202016144A (zh) * 2018-06-21 2020-05-01 日商第一三共股份有限公司 包括cd3抗原結合片段之組成物及其用途
CN115916818A (zh) 2019-12-11 2023-04-04 库利南肿瘤股份有限公司 抗cd19抗体和多特异性结合蛋白
PE20230389A1 (es) * 2020-05-27 2023-03-06 Janssen Biotech Inc Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas
JP7851303B2 (ja) * 2020-09-24 2026-04-24 モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ヒトｃｄ３イプシロンに結合する新規なヒト抗体
CN114656562B (zh) * 2020-12-23 2023-11-03 北京天广实生物技术股份有限公司 结合人和猴cd3的抗体及其应用
WO2022175255A2 (en) 2021-02-16 2022-08-25 Janssen Pharmaceutica Nv Trispecific antibody targeting bcma, gprc5d, and cd3
US12258406B2 (en) 2021-03-24 2025-03-25 Twist Bioscience Corporation Antibodies that bind CD3 Epsilon
CA3213632A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
WO2022228706A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
CN115536740A (zh) * 2021-06-30 2022-12-30 苏州方德门达新药开发有限公司 介导细胞内有效滞留cd3的空间构象表位及其应用
CN113755435B (zh) * 2021-10-15 2023-10-13 苏州药明康德新药开发有限公司 一种食蟹猴pbmc分离方法
WO2023183766A1 (en) * 2022-03-20 2023-09-28 Abcellera Biologics Inc. Anti-cd3 antibodies and t-cell engagers and methods of use
JP2025513714A (ja) * 2022-03-22 2025-04-30 モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｃｄ３に特異的な脱免疫抗体
US20230414750A1 (en) 2022-03-23 2023-12-28 Hoffmann-La Roche Inc. Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
WO2023198727A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
WO2026006495A1 (en) 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anti-wt1/hla-a2 antibody and uses thereof
WO2026006492A2 (en) 2024-06-25 2026-01-02 Ypsilon Therapeutics, Inc. Anti-prame/hla-a2 antibodies and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD272473B3 (de) * 1988-06-13 1993-01-21 Univ Leipzig Verfahren zur herstellung monoklonaler antikoerper gegen die epsilon-kettedes cd 3-antigens humaner t-lymphozyten
JPH0630786A (ja) * 1992-07-14 1994-02-08 Kyowa Hakko Kogyo Co Ltd バイスペシフィック抗体
SG188175A1 (en) * 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
US8236308B2 (en) * 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
SI2155788T1 (sl) * 2007-04-03 2012-11-30 Amgen Res Munich Gmbh Bispecifični vezavni element specifičen za križane vrste
JP6400470B2 (ja) * 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
WO2012162067A2 (en) * 2011-05-21 2012-11-29 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
US20170073415A1 (en) * 2014-05-12 2017-03-16 Numab Ag Novel multispecific molecules and novel treatment methods based on such multispecific molecules

Also Published As

Publication number Publication date
US20200325224A1 (en) 2020-10-15
BR112016022819A2 (pt) 2018-01-16
MX2016015389A (es) 2017-04-13
US20200299385A1 (en) 2020-09-24
EP3149041A1 (en) 2017-04-05
RU2016151235A (ru) 2018-06-28
SG11201609950YA (en) 2016-12-29
AU2015266077A1 (en) 2016-09-29
CN106459201A (zh) 2017-02-22
JP2017516786A (ja) 2017-06-22
CA2942453A1 (en) 2015-12-03
IL247740A0 (en) 2016-11-30
KR20170003591A (ko) 2017-01-09
RU2016151235A3 (enExample) 2019-01-18
WO2015181098A1 (en) 2015-12-03
US20170233475A1 (en) 2017-08-17
EP3763739A1 (en) 2021-01-13

Similar Documents

Publication Publication Date Title
US20200299385A1 (en) Antibodies binding to human and cynomolgus cd3 epsilon
JP7592050B2 (ja) 抗ｈｌａ－ｇ抗体とその使用
US20240270844A1 (en) Anti-tim3 antibodies and methods of use
US20230183349A1 (en) Anti-pd1 antibodies and methods of use
US20250051456A1 (en) Anti-hla-g antibodies and methods of use thereof
HK1231092A1 (en) Antibodies binding to human and cynomolgus cd3 epsilon
HK40044015A (en) Anti-hla-g antibodies and use thereof
HK1259019B (en) Anti-pd1 antibodies and methods of use
HK1197826B (en) Fc-free antibodies comprising two fab fragments and methods of use

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190319

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200226

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20200526

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200707

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200717

R150 Certificate of patent or registration of utility model

Ref document number: 6738285

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees